Insights into Enhancing the chemosensitivity of metastatic breast cancers: Fulvestrant/Faslodex, a selective estrogen receptor down-regulator, sensitizes drug-resistant breast cancer cells by targeting Multidrug Resistance-Associated Protein 2 (MRP2)/ABCC2 through its target gene, 24/April/2014, 13.42

Insights into Enhancing the chemosensitivity of metastatic breast cancers: Fulvestrant/Faslodex, a selective estrogen receptor down-regulator, sensitizes drug-resistant breast cancer cells by targeting Multidrug Resistance-Associated Protein 2 (MRP2)/ABCC2 through its target gene, 24/April/2014, 13.42

Insights into Enhancing the chemosensitivity of metastatic breast cancers: Fulvestrant/Faslodex, a selective estrogen receptor down-regulator, sensitizes drug-resistant breast cancer cells by targeting Multidrug Resistance-Associated Protein 2 (MRP2)/ABCC2 through its target gene, 24/April/2014, 13.42 150 150 Dr Boomi's Genom-2-Discovery Center

Idea Proposed/Formulated by: Dr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To cite: Boominathan, Insights into Enhancing the chemosensitivity of metastatic breast cancers: Fulvestrant/Faslodex, a selective estrogen receptor down-regulator, sensitizes drug-resistant breast cancer cells by targeting Multidrug Resistance-Associated Protein 2 (MRP2)/ABCC2 through its target gene, 24/April/2014, 13.42, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Share
Start Typing